Our breast cancer patients benefit from world-class research, and access to experimental therapies and clinical trials at Stanford, which test today's best practices with potential treatment standards for the future. The collaborative effort among researchers and clinicians at the Women's Cancer Center is yielding important findings that are impacting our patients before, during and after diagnosis with breast cancer.
The BRCA Decision Tool guides the management of cancer risks for BRCA1 and BRCA2 mutation carriers, helping Melanie Lemons understand options and make critical decisions.
- Stem cell research that may help early detection and treatment strategies, and predict reoccurrence
- Improved tumor classification that allows for more personalized treatment options
- Clinical trials with investigational therapies:
- PARP inhibitors, which may be used as preventive therapy for women with an inherited risk of breast cancer, as well as in combination with chemotherapy to maximize outcomes
- Vaccines to prevent HER2-positive breast cancer
- Immunotherapies that corral the immune system in fighting the disease
- Preventive strategies for women at increased risk of breast cancer based on computer modeling
- Improved visualization techniques for finding cancers in dense breast tissue
Before beginning treatment, ask your doctor about any clinical trials you should consider. Learn more about clinical trials for cancer patients.
Clinical trial eligibility flowcharts
Eligibility flowcharts map clinical trials to specific types of cancers to determine if a participant is eligible for the particular clinical trial. View all breast cancer eligibility flowcharts at the Stanford Cancer Institute.